ADMA250516C14000
- 10.12
- 0.000.00%
ADMA Biologics Newsroom
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $35
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $32
ADMA Biologics Analyst Ratings
Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $32
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $25
ADMA Biologics: Strong Growth Prospects and Stability Drive Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $32
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $25
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $25 Price Target
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24
ADMA Biologics Is Maintained at Strong Buy by Raymond James
ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26